NDLI: Identification of miR-143-3p as a diagnostic biomarker in gastric cancer

Content Provider	Springer Nature : BioMed Central
Author	Ju, Yeongdon Choi, Go-Eun Lee, Moon Won Jeong, Myeongguk Kwon, Hyeokjin Kim, Dong Hyeok Kim, Jungho Jin, Hyunwoo Lee, Kyung Eun Hyun, Kyung-Yae Jang, Aelee
Abstract	Background Gastric cancer (GC) is among the most common types of gastrointestinal cancers and has a high incidence and mortality around the world. To suppress the progression of GC, it is essential to develop diagnostic markers. MicroRNAs regulate GC development, but a clearer insight into their role is needed before they can be applied as a molecular markers and targets. Methods In this study, we assessed the diagnostic value of differentially expressed microRNAs as potential diagnostic biomarkers for GC using data for 389 tissue samples from the Cancer Genome Atlas (TCGA) and 21 plasma samples from GC patients. Results The expression of hsa-miR-143-3p (also known as hsa-miR-143) was significantly downregulated in GC according to the TCGA data and plasma samples. The 228 potential target genes of hsa-miR-143-3p were analyzed using a bioinformatics tool for miRNA target prediction. The target genes correlated with extracellular matrix organization, the cytoplasm, and identical protein binding. Furthermore, the pathway enrichment analysis of target genes showed that they were involved in pathways in cancer, the phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt) signaling pathway, and proteoglycans in cancer. The hub genes in the protein–protein interaction (PPI) network, were matrix metallopeptidase 2 (MMP2), CD44 molecule (CD44), and SMAD family member 3 (SMAD3). Conclusions This study suggests that hsa-miR-143-3p may be used as a diagnostic marker for GC, contributing via the pathways involved in the development of GC.
Related Links	https://bmcmedgenomics.biomedcentral.com/counter/pdf/10.1186/s12920-023-01554-3.pdf
Ending Page	16
Page Count	16
Starting Page	1
File Format	HTM / HTML
ISSN	17558794
DOI	10.1186/s12920-023-01554-3
Journal	BMC Medical Genomics
Issue Number	1
Volume Number	16
Language	English
Publisher	BioMed Central
Publisher Date	2023-06-16
Access Restriction	Open
Subject Keyword	Human Genetics Microarrays Gene Expression Gastric cancer miR-143-3p Biomarker Bioinformatics Diagnosis
Content Type	Text
Resource Type	Article
Subject	Genetics (clinical) Genetics
Journal Impact Factor	2.1/2023
5-Year Journal Impact Factor	2.5/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

MiR-455-3p inhibits gastric cancer progression by repressing Wnt/β-catenin signaling through binding to ARMC8

Unveiling the role of miR-137-3p/miR-296-5p/SERPINA3 signaling in colorectal cancer progression: integrative analysis of gene expression profiles and in vitro studies

CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer

The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile

Analyzing the expression and clinical significance of CENPE in gastric cancer

Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration.

The circular RNA hsa_circ_000780 as a potential molecular diagnostic target for gastric cancer

miR-22-3p as a potential biomarker for coronary artery disease based on integrated bioinformatics analysis

A predictive model for assessing prognostic risks in gastric cancer patients using gene expression and methylation data

Identification of miR-143-3p as a diagnostic biomarker in gastric cancer

Similar Documents

MiR-455-3p inhibits gastric cancer progression by repressing Wnt/β-catenin signaling through binding to ARMC8

Unveiling the role of miR-137-3p/miR-296-5p/SERPINA3 signaling in colorectal cancer progression: integrative analysis of gene expression profiles and in vitro studies

CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer

The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile

Analyzing the expression and clinical significance of CENPE in gastric cancer

Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration.

The circular RNA hsa_circ_000780 as a potential molecular diagnostic target for gastric cancer

miR-22-3p as a potential biomarker for coronary artery disease based on integrated bioinformatics analysis

A predictive model for assessing prognostic risks in gastric cancer patients using gene expression and methylation data

Identification of miR-143-3p as a diagnostic biomarker in gastric cancer